Product Images Tetrabenazine

This is a graph indicating the Chorea Score changes in patients with HD (Huntington's Disease) treated with Placebo and Tetrabenazine. The study includes 84 patients, 54 of whom were treated with Tetrabenazine, while 30 received Placebo. The Chorea Scores were measured and recorded over a period of 13 weeks (Study Week). There was a significant improvement in patients treated with Tetrabenazine when compared to the Placebo group. There were error bars and the significance level (p-value) is less than 0.05.*

This is a graph with two lines indicating the change in the total chorea score of patients in two different treatment groups, Tetrabenazine and Placebo. The graph shows the cumulative percentage of patients on the Y-axis, with specified changes from baseline chorea score on the X-axis. There are two sets of data points for each change in score, one for Tetrabenazine and one for Placebo. The percentages of randomized patients within each treatment group who completed Study 1 are also provided.*

Each tablet of this medication contains 25 mg of tetrabenazine. The recommended dosage can be found in the package insert. Store between 20°C to 25°C. Dispense in a child-resistant container and do not use if the seal is missing or broken. Keep out of reach of children. This medication is distributed by Sun Pharmaceutical Industries, Inc. and manufactured by Sun Pharmaceutical Industries Limited in India. The batch number and expiration date are not available.*